Video: BSP Pharma Inc. Announces Groundbreaking Findings from The Australian Centre for Complementary Medicine Education and Research Joint Health Clin...(et is a model for responsible developmen...),Health

The research was designed to bring together a large number of previous studies, to confirm the efficacy of shea extract in humans and to further demonstrate the safety of FlexNow. FlexNow is one of only 7 dietary supplements to be accepted by the FDA in 2004 as meeting all safety requirements, which was further shown during the clinical study when there was no difference in adverse effects between FlexNow and placebo.

The biggest clinical surprise was the unprecedented reduction in the breakdown of cartilage, both compared to placebo and for that reported for glucosamine. The other remarkable findings were the strong reduction in inflammatory markers that are produced more in unhealthy joints and joint cartilage than normal joints, and high sensitivity C-reactive protein (hsCRP), which has been found to be higher in patients with unhealthy joints than controls.

"This clinical confirmation that FlexNow is significantly reducing cartilage breakdown and inflammation, gives us insight into why so many FlexNow Joint Formula users are telling us of their joint relief for the first time," said Leonard P. Smith, CEO and President, BSP Pharma Inc., "which is allowing so many people with joint pain to once again lead an active life."

The clinical study is being submitted for publication. Prior clinical studies can be found by visiting http://www.flexnow.us

(1) Christgau S, Henrotin Y, Tanko LB, et al. Osteoarthritic patients with

high cartilage turnover show increased responsiveness to the cartilage

protecting effects of glucosamine sulphate. Clin Exp Rheumatol 2004;

22:36-42.